Myriad Genetics (NASDAQ:MYGN) Updates FY25 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.07-0.11 for the period, compared to the consensus EPS estimate of $0.15. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $879.47 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MYGN. UBS Group initiated coverage on Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. Bank of America lowered their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a report on Friday, December 13th. Piper Sandler reduced their price objective on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. Morgan Stanley lowered their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th. Finally, StockNews.com raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Myriad Genetics currently has an average rating of “Hold” and an average price target of $24.27.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $13.15 on Thursday. The company has a 50-day moving average price of $14.89 and a two-hundred day moving average price of $22.04. Myriad Genetics has a twelve month low of $12.81 and a twelve month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.20 billion, a PE ratio of -10.12 and a beta of 1.89.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.